Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise insulin intensification with biphasic insulin aspart 30 versus basal-bolus therapy in insulin-naive adults with type 2 diabetes
2014-003708-62Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing BIAsp 30 stepwise intensification with Basal-bolus therapy with insulin glargine and insulin aspart (2 arms). Primary endpoint: Change from baseline in HbA1c. Started Apr 2015; status: completed.
02
Drugs
biphasic insulin aspartinsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003708-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003708-62.